|
1
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sathornsumetee S and Rich JN: New
treatment strategies for malignant gliomas. Expert Rev Anticancer
Ther. 6:1087–1104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nogueira L, Ruiz-Ontañon P,
Vazquez-Barquero A, Lafarga M, Berciano MT, Aldaz B, Grande L,
Casafont I, Segura V, Robles EF, et al: Blockade of the NFκB
pathway drives differentiating glioblastoma-initiating cells into
senescence both in vitro and in vivo. Oncogene. 30:3537–3548. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Woo JS, Kim SM, Jeong CH, Ryu CH and Jeun
SS: Lipoxygenase inhibitor MK886 potentiates TRAIL-induced
apoptosis through CHOP- and p38 MAPK-mediated up-regulation of
death receptor 5 in malignant glioma. Biochem Biophys Res Commun.
431:354–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kim SM, Park JG, Baek WK, Suh MH, Lee H,
Yoo SK, Jung KH, Suh SI and Jang BC: Cadmium specifically induces
MKP-1 expression via the glutathione depletion-mediated p38 MAPK
activation in C6 glioma cells. Neurosci Lett. 440:289–293. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Posser T, de Aguiar CB, Garcez RC, Rossi
FM, Oliveira CS, Trentin AG, Neto VM and Leal RB: Exposure of C6
glioma cells to Pb(II) increases the phosphorylation of p38(MAPK)
and JNK1/2 but not of ERK1/2. Arch Toxicol. 81:407–414. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshino Y, Aoyagi M, Tamaki M, Duan L,
Morimoto T and Ohno K: Activation of p38 MAPK and/or JNK
contributes to increased levels of VEGF secretion in human
malignant glioma cells. Int J Oncol. 29:981–987. 2006.PubMed/NCBI
|
|
9
|
Zhang Z, Lv J, Lei X, Li S, Zhang Y, Meng
L, Xue R and Li Z: Baicalein reduces the invasion of glioma cells
via reducing the activity of p38 signaling pathway. PLoS One.
9:e903182014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang D, Lin J and Han J:
Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol.
7:243–249. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yin X, Krikorian P, Logan T and Csizmadia
V: Induction of RIP-2 kinase by proinflammatory cytokines is
mediated via NF-kappaB signaling pathways and involves a novel
feed-forward regulatory mechanism. Mol Cell Biochem. 333:251–259.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thome M, Hofmann K, Burns K, Martinon F,
Bodmer JL, Mattmann C and Tschopp J: Identification of CARDIAK, a
RIP-like kinase that associates with caspase-1. Curr Biol.
8:885–888. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Navas TA, Baldwin DT and Stewart TA: RIP2
is a Raf1-activated mitogen-activated protein kinase kinase. J Biol
Chem. 274:33684–33690. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jacquet S, Nishino Y, Kumphune S, Sicard
P, Clark JE, Kobayashi KS, Flavell RA, Eickhoff J, Cotten M and
Marber MS: The role of RIP2 in p38 MAPK activation in the stressed
heart. J Biol Chem. 283:11964–11971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McCully ML, Baroja ML, Chau TA, Jain AK,
Barra L, Salgado A, Blake PG and Madrenas J: Receptor-interacting
protein 2 is a marker for resolution of peritoneal
dialysis-associated peritonitis. Kidney Int. 72:1273–1281. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hollenbach E, Vieth M, Roessner A, Neumann
M, Malfertheiner P and Naumann M: Inhibition of RICK/nuclear
factor-kappaB and p38 signaling attenuates the inflammatory
response in a murine model of Crohn disease. J Biol Chem.
280:14981–14988. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Humphries F, Yang S, Wang B and Moynagh
PN: RIP kinases: Key decision makers in cell death and innate
immunity. Cell Death Differ. 22:225–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goh FY, Cook KL, Upton N, Tao L, Lah LC,
Leung BP and Wong WS: Receptor-interacting protein 2 gene silencing
attenuates allergic airway inflammation. J Immunol. 191:2691–2699.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singel SM, Batten K, Cornelius C, Jia G,
Fasciani G, Barron SL, Wright WE and Shay JW: Receptor-interacting
protein kinase 2 promotes triple-negative breast cancer cell
migration and invasion via activation of nuclear factor-kappaB and
c-Jun N-terminal kinase pathways. Breast Cancer Res. 16:R282014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang H and Chin AI: Role of Rip2 in
development of tumor-infiltrating MDSCs and bladder cancer
metastasis. PLoS One. 9:e947932014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai X, Du J, Liu Y, Xia W, Liu J, Zou M,
Wang Y, Wang M, Su H and Xu D: Identification and characterization
of receptor-interacting protein 2 as a TNFR-associated factor 3
binding partner. Gene. 517:205–211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Häcker H, Redecke V, Blagoev B,
Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Häcker
G, et al: Specificity in Toll-like receptor signalling through
distinct effector functions of TRAF3 and TRAF6. Nature.
439:204–207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hildebrand JM, Yi Z, Buchta CM, Poovassery
J, Stunz LL and Bishop GA: Roles of tumor necrosis factor receptor
associated factor 3 (TRAF3) and TRAF5 in immune cell functions.
Immunol Rev. 244:55–74. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai X, Wang M, Kong H, Liu J, Liu Y, Xia
W, Zou M, Wang J, Su H and Xu D: Prokaryotic expression,
purification and functional characterization of recombinant human
RIP2. Mol Biol Rep. 40:59–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lupfer C, Thomas PG, Anand PK, Vogel P,
Milasta S, Martinez J, Huang G, Green M, Kundu M, Chi H, et al:
Receptor interacting protein kinase 2-mediated mitophagy regulates
inflammasome activation during virus infection. Nat Immunol.
14:480–488. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Magalhaes JG, Lee J, Geddes K, Rubino S,
Philpott DJ and Girardin SE: Essential role of Rip2 in the
modulation of innate and adaptive immunity triggered by Nod1 and
Nod2 ligands. Eur J Immunol. 41:1445–1455. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tigno-Aranjuez JT, Asara JM and Abbott DW:
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven
cytokine responses. Genes Dev. 24:2666–2677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nogueira L, Ruiz-Ontañon P,
Vazquez-Barquero A, Moris F and Fernandez-Luna JL: The NFκB
pathway: A therapeutic target in glioblastoma. Oncotarget.
2:646–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tchoghandjian A, Jennewein C, Eckhardt I,
Rajalingam K and Fulda S: Identification of non-canonical NF-κB
signaling as a critical mediator of Smac mimetic-stimulated
migration and invasion of glioblastoma cells. Cell Death Dis.
4:e5642013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao X, Laver T, Hong SW, Twitty GB Jr,
Devos A, Devos M, Benveniste EN and Nozell SE: An NF-κB p65-cIAP2
link is necessary for mediating resistance to TNF-α induced cell
death in gliomas. J Neurooncol. 102:367–381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie P, Kraus ZJ, Stunz LL and Bishop GA:
Roles of TRAF molecules in B lymphocyte function. Cytokine Growth
Factor Rev. 19:199–207. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Saha SK and Cheng G: TRAF3: A new
regulator of type I interferons. Cell Cycle. 5:804–807. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Annunziata CM, Davis RE, Demchenko Y,
Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W,
et al: Frequent engagement of the classical and alternative
NF-kappaB pathways by diverse genetic abnormalities in multiple
myeloma. Cancer Cell. 12:115–130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Keats JJ, Fonseca R, Chesi M, Schop R,
Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, et al:
Promiscuous mutations activate the noncanonical NF-kappaB pathway
in multiple myeloma. Cancer Cell. 12:131–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie P, Kraus ZJ, Stunz LL, Liu Y and
Bishop GA: TNF receptor-associated factor 3 is required for T
cell-mediated immunity and TCR/CD28 signaling. J Immunol.
186:143–155. 2011. View Article : Google Scholar : PubMed/NCBI
|
